Trial  country	Treatment regimen	Blinding	SAE		Discontinuation		Lab and other	Notes
			TR	AC	TR	AC
	P. vivax
Dunne 2005a India	1) Azithromycin 1 g/day for 3 days	P	0	0	0	NR	NR	2 discontinued in arm 2 because of pruritis (1) and maculopapular rash (1)
	2) Chloroquine 0.6 g on day 1 to 2, 0.3 g on day 3	P	0	0	2	NR	NR
Pukrittayakamee 2001 Thailand	1) Azithromycin 0.5 g/day for 3 days	O	0	0	NR	NR		"None of the patients developed serious adverse effects as monitored by clinical symptoms and laboratory data."
	2) Tetracycline 250 mg 4x/day for 7 days	O	0	0	NR	NR
	3) Doxycycline 200 mg/day for 7 days	O	0	0	NR	NR
	4) Clindamycin 300 mg 4x/day for 7 days	O	0	0	NR	NR
	P. falciparum
Dunne 2005b India	1) Azithromycin 1 g/day for 3 days	P	0	0	0	0	NR
	2) Chloroquine 0.6 g on day 1 to 2, 0.3 g on day 3	P	0	0	0	0	NR
	3) Azithromycin 1 g/day for 3 days, chloroquine 0.6 g on day 1 to 2, 0.3 g on day 3	O	0	0	0	0	NR
Krudsood 2000 Thailand	1) Azithromycin 0.5 g/day, artesunate 200 mg/day for 3 days	O	0	0	NR	NR	"Several patients had abnormal haematology and biochemistry at the beginning, but all of these improved a few weeks after treatment."
	2) Artesunate 200 mg/day for 3 days, mefloquine 10 mg/kg on day 1 to 2, 5 mg/kg on day 3	O	0	0	NR	NR
	3) Artesunate 200 mg/day for 3 days	O	0	0	NR	NR
Miller 2006 Thailand	1) Azithromycin 0.5 g 2x/day and quinine 10 mg/kg 3x/day for 3 days	O	0	0	NR	NR	Elevated ALT level (1 in each group). Resolved within 10 days of completion of therapy.	Most side effects related to quinine (tinnitus, prolonged QTc)
	2) Azithromycin 0.5 g 2x/day and quinine 10 mg/kg 3x/day for 5 days	O	0	0	NR	NR
	3) Azithromycin 0.5 g 3x/day and quinine 10 mg/kg 3x/day for 3 days	O	0	0	NR	NR
	4) Doxycycline 100 mg 2x/day and quinine 10 mg/kg 3x/day for 7 days	O	0	0	NR	NR
Na‐Bangchang 1996 Thailand	1) Azithromycin 0.5 g at start, 0.25 g at 24 hours and 48 hours, and artemether 300 mg at start	O	0	0	NR	NR	NR	"Transient mild nausea, abdominal discomfort and loss of appetite were common adverse effects."
	2) Doxycycline 100 mg 2x/day for 5 days and artemether 300 mg at start and 100 mg after 12 hours	O	0	0	NR	NR	NR
Noedl 2006 Thailand	1) Azithromycin 0.75 g 2x/day and artesunate 100 mg 2x/day for 3 days	O	0	0	0	0	NR	One participant with food poisoning withdrawn in arm 4.
	2) Azithromycin 1 g/day and artesunate 200 mg/day for 3 days	O	0	0	0	0	NR
	3) Azithromycin 0.75 g 2x/day and quinine 10 mg/kg 2x/day for 3 days	O	0	0	0	0	ECG: quinine groups significant prolongation of QT interval.
	4) Azithromycin 0.5 g 3x/day and quinine 10 mg/kg 3x/day for 3 days	O	0	1	0	0
Pfizer74841 India	1) Azithromycin 1 g/day and chloroquine 0.6 g/day for 3 days	P/O	0/83	5/83 (6.0%)	0	3/83 (3.6%)	“No clinical significant laboratory findings or changes in vital signs."	SEA any cause: arm 1: cerebral malaria (1), fever (4); arm 2:  fever (3), convulsion (1), pneumonia (1); arm 3: fever (2), abnormal behaviour (1, TR).
	2) Azithromycin  0.5 g/day and chloroquine 0.6 g/day for 3 days	P	0/67	5/67 (7.5%)	0	0/67		Discontinuations: 1 cerebral malaria and 2 malarial fever in arm 1, and 1 malarial fever in arm 3.
	3) Sulfadoxine‐pyrimethamine 1500mg /75 mg at start, chloroquine 0.6 g on day 1 to 2, 0.3 mg on day 3	O	1/80 (1.3%)	3/80 (3.8%)	0	1/80 (1.3%)
Pfizer 82563 Kenya	1) Azithromycin 1 g/day and chloroquine 0.6 g/day for 3 days	P	0	1/6 (16.7%)	0	0	Similar incidence of lab abnormalities in both groups. "None were unexpected for this population." Vital signs: larger mean decrease in BP and larger mean increase in heart rate from baseline in group 2.	One SEA in group 1 (seizures) in a person with a history of seizures.
	2) Chloroquine 0.6 g/day for 3 days	P	0	0	0	0
Pfizer 82576 Ghana, Kenya, Mali, Uganda, Zambia	1) Azithromycin 1 g/day and chloroquine 0.6 g/day for 3 days	P	0	1/114 (0.9%)	2/114 (1.8%)	3/114 (2.6%)	"The incidence of laboratory abnormalities was similar in arm 1 and arm 3."	SEA: Dyspnoea and confusional state in arm 1, mental disorder and nephritic syndrome in arm 3 (TR)
	2) Azithromycin 0.5 g/day and chloroquine 0.6 g/day for 3 days	P	0	0	0	0		Discontinuations: arm 1: confusion 1, vomiting 2 (TR), arm 3: vomiting 2, (1 TR), jaundice 1, fever 1 (TR)
	3) Mefloquine 750 mg at start, 500 mg after 6 hours	P	2/115 (1.7%)	2/115 (1.7%)	2/115 (1.7%)	4/115 (3.5%)
Pfizer 84227 Colombia/Surinam	1) Azithromycin 1 g/day and chloroquine 0.6 g/day for 3 days	P	NR	3/114 (2.6%)	NR	6/114 (5.3%)	NR	SEA: Arm 1: complicated malaria, progressive renal failure, sepsis; arm 2: enterocolitis; arm 3: diabetic neuropathy, progressive severe anaemia.
	2) Azithromycin 0.5 g/day and chloroquine 0.6 g/day for 3 days	P	NR	1/14 (7.1%)	NR	NR	NR	Discontinuations: Arm 1: vomiting 2, infection 2, sepsis 1, electrolyte imbalance 1; arm 3: infection 1.
	3) Atovaquone 1000 mg/day and proguanil 400 mg/day for 3 days	P	NR	2/116 (1.7%)	NR	1/116 (0.9%)	NR
Pfizer 84240 Indonesia	1) Azithromycin 1 g/day and chloroquine 0.6 g/day for 3 days	P	0	1/13 (7.7%)	0	0	"All treatment groups showed a similar incidence of laboratory abnormalities (1 subject in each group) with regard to normal baseline. None of the laboratory abnormalities was unexpected for this disease population."	SEA  arm 1: recurrent malaria; arm 2: appendicitis
	2) Azithromycin 0.5 g/day and chloroquine 0.6 g/day for 3 days	P	0	1/7 (14.3%)	0	0
	3) Sulfadoxine‐Pyrimethamine 1500 mg/75 mg at start, chloroquine 0.6 g on day 1 to 2, 0.3 g on day 3	P	0	0/12	0	0
Pfizer 367653 Burkina Faso, Ghana, Kenya, Mali, Senegal, Zambia	1) Azithromycin 1 g/day and chloroquine 0.6 g/day for 3 days	O	0/113	0/113	NR	1/113 (0.9%)	"No subjects were discontinued from the study due to abnormal laboratory test results."	SEA: dizziness and intentional self injury
	2) Mefloquine 750 mg at start, 500 mg after 6 to 10 hours	O	1/116 (0.9%)	2/116 (1.7%)	NR	0/116		Discontinuation in arm 1 because of pruritis
Sykes 2009 Tanzania	1) Azithromycine 20 mg/kg/day and artesunate 4 mg/kg/day for 3 days	O	1/120				Lab‐abnormalities on day 14: 18/120
	2) Artemether 20 mg and lumefantrine 120 mg 2x/day for <15 kg and 40 mg/240 mg 2x/day for ≥15 kg for 3 days	O	9/129				Lab‐abnormalities on day 14: 22/121
Thriemer 2010 Bangladesh	1) Azithromycin 1.5 g/day and artesunate 200 mg/day for 3 days. Children < 35 kg: azithromycin 30 mg/kg/day, and artesunate 4 mg/kg/day for 3 days.	O		0		8	NR	Discontinuations: Development of P. vivax ≥ day 21
	2) Artemether 80 mg and lumefantrine 480 mg 2x/day for 3 days. Children < 35 kg: artemether 4 mg/kg and lumefantrine 24 mg/kg 2x/day for 3 days	O		0		4	NR
	Excluded studies (P. falciparum)
Krudsood 2002 Thailand	1) Azithromycin 0.5 g/day and dihydroartemisinin 80 mg/day for 3 days	O	0	0	0	0	"Some baseline laboratory parameters were affected by disease status. However, they all returned to normal within 1‐2 weeks."
	2) Mefloquine 10 mg/kg on day 1 and 2, and 5 mg/kg on day 3, dihydroartemisinin 80 mg/day for 3 days		0	0	0	0
Pfizer 282919 India, Colombia	1) Azithromycin 2 g/day and chloroquine 0.6 g/day for 3 days	O	0	NR	0	NR